Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Zometa in Bone Metastases from Nasopharyngeal Cancer
NCT00697619Phase 2Completed
- Sponsor
- Sun Yat-sen University
- Start
- Sep 2005
- Primary completion
- Jan 2009
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of zoledronic acid in nasopharyngeal carcinoma (NPC) and bone metastasis, sponsored by Sun Yat-sen University. Primary endpoint: Urinary N-telopeptide at 3 months. Started Sep 2005; status: completed.
02
Drugs
zoledronic acid
03
Conditions
nasopharyngeal carcinoma (NPC)bone metastasis
Beyond the preview
Go deeper on NCT00697619.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00697619.